ArticleJournal of the American Society for Mass Spectrometry2026
Automated Enzymatic Deglycosylation of Monoclonal Antibody with the SampleStream Platform.
Article in Journal of the American Society for Mass Spectrometry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Engineered monoclonal antibodies have proven themselves as invaluable biotherapeutics used in clinics worldwide. In discovery, development, and production, it is essential that they are accurately validated to ensure their homogeneity, consistency, safety, and effectiveness, which are commonly conducted via mass spectrometric analysis. However, validation processes can be manual, time-consuming, and costly. One hindrance in the analytical workflow is the relatively long time required to deglycosylate native mAbs with PNGase F on the benchtop, which is usually done to reduce the spectral complexity, increase the ionization efficiency, and facilitate the identification of glycosylation sites. To circumvent this obstacle, a workflow on the SampleStream Platform was developed and optimized to automate in-channel PNGase F-mediated deglycosylation of native monoclonal antibody at unprecedented speed, accomplishing 86% deglycosylation in 3 min. The presented workflow offers a promising strategy to reduce discovery and development costs and streamline the characterization of antibody-based biopharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.